EA201000102A1 - Антагонистические антитела к активируемому протеазой рецептору-1 (par1) - Google Patents

Антагонистические антитела к активируемому протеазой рецептору-1 (par1)

Info

Publication number
EA201000102A1
EA201000102A1 EA201000102A EA201000102A EA201000102A1 EA 201000102 A1 EA201000102 A1 EA 201000102A1 EA 201000102 A EA201000102 A EA 201000102A EA 201000102 A EA201000102 A EA 201000102A EA 201000102 A1 EA201000102 A1 EA 201000102A1
Authority
EA
Eurasian Patent Office
Prior art keywords
par1
receptor
proteasous
activated
antagonistic antibodies
Prior art date
Application number
EA201000102A
Other languages
English (en)
Inventor
Кеннет Р. Льюрсен
Original Assignee
Айрм Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Айрм Ллк filed Critical Айрм Ллк
Publication of EA201000102A1 publication Critical patent/EA201000102A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

В заявке описаны антитела или антигенсвязывающие молекулы, которые специфически распознают и являются антагонистами PAR1-рецептора. В заявке описаны также полинуклеотиды и векторы, которые кодируют указанные молекулы, и клетки-хозяева, которые несут полинуклеотиды или векторы.
EA201000102A 2007-07-17 2008-07-17 Антагонистические антитела к активируемому протеазой рецептору-1 (par1) EA201000102A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95029007P 2007-07-17 2007-07-17
PCT/US2008/070357 WO2009012401A1 (en) 2007-07-17 2008-07-17 Antagonist antibodies of protease activated receptor-1 (par1)

Publications (1)

Publication Number Publication Date
EA201000102A1 true EA201000102A1 (ru) 2010-12-30

Family

ID=39810256

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000102A EA201000102A1 (ru) 2007-07-17 2008-07-17 Антагонистические антитела к активируемому протеазой рецептору-1 (par1)

Country Status (10)

Country Link
US (1) US20100330090A1 (ru)
EP (1) EP2176297A1 (ru)
JP (1) JP2010533732A (ru)
KR (1) KR20100021657A (ru)
CN (1) CN101977936A (ru)
AU (1) AU2008275992A1 (ru)
BR (1) BRPI0813833A2 (ru)
CA (1) CA2693201A1 (ru)
EA (1) EA201000102A1 (ru)
WO (1) WO2009012401A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160045506A1 (en) * 2013-03-15 2016-02-18 University Of Rochester Use of inhibitors of binding between a par-1 receptor and its ligands for the treatment of glioma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2378473A1 (en) * 1999-07-23 2001-02-01 The Regents Of The University Of California Modulation of platelet activation
US20060216290A1 (en) * 2003-03-11 2006-09-28 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled protease activated receptor 1 (Par1)
EP1761561B1 (en) * 2004-01-20 2015-08-26 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
PT3540062T (pt) * 2004-11-16 2021-07-06 Humanigen Inc Permuta de cassete de região variável de imunoglobulina
US7888483B2 (en) * 2006-07-18 2011-02-15 Irm Llc Antagonists of protease activated receptor-1 (PAR1)

Also Published As

Publication number Publication date
EP2176297A1 (en) 2010-04-21
CA2693201A1 (en) 2009-01-22
WO2009012401A1 (en) 2009-01-22
JP2010533732A (ja) 2010-10-28
KR20100021657A (ko) 2010-02-25
CN101977936A (zh) 2011-02-16
BRPI0813833A2 (pt) 2015-01-06
US20100330090A1 (en) 2010-12-30
AU2008275992A1 (en) 2009-01-22

Similar Documents

Publication Publication Date Title
EA201001139A1 (ru) УЛУЧШЕННЫЕ АНТИТЕЛА АНТИ-TrkB
JOP20190017A1 (ar) أجسام مضادة ترتبط مع مستقبل cgrp بشري
EA201990578A1 (ru) Связывающие молекулы, которые модулируют биологическую активность, проявляемую клеткой
PE20140232A1 (es) Proteinas de enlace antigeno capaz de enlazar linfopoyetina estromal timica
PH12015500806B1 (en) Binding molecules to the human ox40 receptor
EA201791940A2 (ru) Варианты полипептидов рецептора iib активина и их использование
EA201170030A1 (ru) Il-6-опосредованная иммунотерапия
EA201001223A1 (ru) Стабилизированные белковые композиции
MX2009008104A (es) Hepcidina, antagonistas de hepcidina y metodos de uso.
EA201692039A1 (ru) ИММУНОГЛОБУЛИНЫ, СВЯЗЫВАЮЩИЕ ЧЕЛОВЕЧЕСКИЕ Vγ9Vδ2 Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ
EA201000717A1 (ru) Молекулы и способы, предназначенные для модуляции компонента системы комплемента
EA202092589A2 (ru) Cxcr2-связывающие полипептиды
EA201000844A1 (ru) Связывающие wise агенты и эпитопы
BRPI0812248A2 (pt) agentes de ligação ao receptor fc de região constante de imunoglobulina
DK2681244T3 (da) Cea-antistoffer
CR11691A (es) Anticuerpos monoclonales contra la proteína rgm a y sus usos
EA201500316A1 (ru) Антагонисты толл-подобного рецептора 3
MY161435A (en) Anti-vegf antibodies and polynucleotides encoding the same
EA200900403A1 (ru) Соединения, которые модулируют рецептор св2
EA201100523A1 (ru) Соединения сульфонила, которые селективно модулируют рецептор св2
DK1957517T3 (da) Anvendelse af peptider, der binder til TPO-receptor
EA200700944A1 (ru) Миметические антитела, связывающие меланокортиновый рецептор, композиции, способы и применение
NO20092743L (no) Antistoffer mot CD200R
EA201892440A1 (ru) Антитела к tl1a и их применения
EA201171307A1 (ru) Антагонисты толл-подобного рецептора 3